NEW YORK (GenomeWeb News) – Vermillion reported after the close of the market Thursday that its third quarter revenues were down 2 percent year over year at $323,000 versus $330,000 in Q3 2013.

The company posted product revenue of $209,000, down 3 percent from $216,000 in Q3 2013. That revenue was based on 4,325 OVA1 ovarian cancer tests performed in Q3 2014 versus 4,328 tests performed in the year-ago period.

License revenue was flat at $114,000.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.